Lilly's diabetes and obesity leader to retire in broader leadership shuffle as CSO Dan Skovronsky takes on immunology role

Kyle LaHucik

Senior Reporter

As Eli Lilly anticipates an FDA weight loss approval for its in-demand diabetes drug Mounjaro by year’s end, the drugmaker’s leader of those two areas …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly's diabetes and obesity leader to retire in broader leadership shuffle as CSO Dan Skovronsky takes on immunology role

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Lil­ly's di­a­betes and obe­si­ty leader to re­tire in broad­er lead­er­ship shuf­fle as CSO Dan Skovron­sky takes on im­munol­o­gy role

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Lilly's diabetes and obesity leader to retire in broader leadership shuffle as CSO Dan Skovronsky takes on immunology role